A one-year prospective, randomised, placebo-controlled, double-blind, phase II/III safety trial of combination therapy with IFN beta-1a (Avonex®) and mycophenolate mofetil (Cellcept®) in early multiple sclerosis

被引：0
|
作者：
Remington, G. [1 ]
Treadaway, K. [1 ]
Frohman, T. [1 ]
Shah, A. [1 ]
Salter, A. [1 ]
Racke, M. [1 ]
Frohman, E. [1 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S244 / S244
页数：1
相关论文
共 50 条
  • [1] Treatment of multiple sclerosis with a combination of interferon beta-1a (Avonex) and Mycophenolate mofetil (Cellcept): Results of a phase II clinical trial
    Vermersch, P
    Waucquier, N
    Bourteel, H
    Stojkovic, T
    Ferriby, D
    Michelin, E
    de Seze, J
    NEUROLOGY, 2004, 62 (07) : A259 - A259
  • [2] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
    Kappos, Ludwig
    Hartung, Hans-Peter
    Freedman, Mark S.
    Boyko, Alexey
    Radue, Ernst Wilhelm
    Mikol, Daniel D.
    Lamarine, Marc
    Hyvert, Yann
    Freudensprung, Ulrich
    Plitz, Thomas
    van Beek, Johan
    LANCET NEUROLOGY, 2014, 13 (04): : 353 - 363
  • [3] Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
    Filippi, M
    Rovaris, M
    Inglese, M
    Barkhof, F
    De Stefano, N
    Smith, S
    Comi, G
    LANCET, 2004, 364 (9444): : 1489 - 1496
  • [4] Rituximab in patients with primary progressive multiple sclerosis: demographics in a Phase II/III randomised, double-blind, placebo-controlled multicentre trial
    Hawker, K.
    Freedman, M. S.
    O'Connor, P.
    Calabresi, P.
    Antel, J. P.
    Pallitch, H.
    Simon, J.
    Hauser, S.
    Sarkar, N.
    Agarwal, S.
    Langer-Gould, A.
    Smith, C.
    MULTIPLE SCLEROSIS, 2007, 13 : S165 - S165
  • [5] Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
    Kappos, Ludwig
    Arnold, Douglas L.
    Bar-Or, Amit
    Camm, John
    Derfuss, Tobias
    Kieseier, Bernd C.
    Sprenger, Till
    Greenough, Kristin
    Ni, Pingping
    Harada, Tomohiko
    LANCET NEUROLOGY, 2016, 15 (11): : 1148 - 1159
  • [6] Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial
    Miller, David H.
    Weber, Thomas
    Grove, Richard
    Wardell, Claire
    Horrigan, Joseph
    Graff, Ole
    Atkinson, Gillian
    Dua, Pinky
    Yousry, Tarek
    MacManus, David
    Montalban, Xavier
    LANCET NEUROLOGY, 2012, 11 (02): : 131 - 139
  • [7] Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial
    Ravnborg, Mads
    Sorensen, Per Soelberg
    Andersson, Magnus
    Celius, Elisabeth G.
    Jongen, Peter J.
    Elovaara, Irina
    Bartholome, Emmanuel
    Constantinescu, Cris S.
    Beer, Karsten
    Garde, Ellen
    Sperling, Bjorn
    LANCET NEUROLOGY, 2010, 9 (07): : 672 - 680
  • [8] Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial
    Mankikian, Julie
    Caille, Agnes
    Reynaud-Gaubert, Martine
    Agier, Marie-Sara
    Bermudez, Julien
    Bonniaud, Philippe
    Borie, Raphael
    Brillet, Pierre-Yves
    Cadranel, Jacques
    Court-Fortune, Isabelle
    Crestani, Bruno
    Debray, Marie-Pierre
    Gomez, Emmanuel
    Gondouin, Anne
    Hirschi-Santelmo, Sandrine
    Israel-Biet, Dominique
    Jouneau, Stephane
    Juvin, Karine
    Leger, Julie
    Kerjouan, Mallorie
    Marquette, Charles-Hugo
    Naccache, Jean-Marc
    Nunes, Hilario
    Plantier, Laurent
    Prevot, Gregoire
    Quetant, Sebastien
    Traclet, Julie
    Valentin, Victor
    Uzunhan, Yurdagul
    Wemeau-Stervinou, Lidwine
    Bejan-Angoulvant, Theodora
    Cottin, Vincent
    Marchand-Adam, Sylvain
    EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (06)
  • [9] The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study
    Bodtger, U
    Poulsen, LK
    Jacobi, HH
    Malling, HJ
    ALLERGY, 2002, 57 (04) : 297 - 305
  • [10] Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial
    Chitnis, Tanuja
    Banwell, Brenda
    Kappos, Ludwig
    Arnold, Douglas L.
    Guecueyener, Kivilcim
    Deiva, Kumaran
    Skripchenko, Natalia
    Cui, Li-Ying
    Saubadu, Stephane
    Hu, Wenruo
    Benamor, Myriam
    Le-Halpere, Annaig
    Truffinet, Philippe
    Tardieu, Marc
    LANCET NEUROLOGY, 2021, 20 (12): : 1001 - 1011
12345